Technology area: Biotechnology & Pharmaceuticals
21 pending office actions • 17 art units • 21 examiners • 0 of 21 (0%) have an AI response strategy ready • 23 patents granted in the last 365 days
The Catholic University Of Korea Industry Academic Cooperation Foundation currently manages 1 pending office action within the Chemistry & Materials technology area. This action is assigned to 1 distinct examiner working within 1 distinct art unit. The presence of 1 distinct examiner for 1 pending office action indicates that the company's active legal engagement is limited to this technical review process. This arrangement of the assigned examiner and the assigned art unit defines the company's current prosecution efforts at the patent office.
The busiest examiner for this portfolio is WECKER, JENNIFER, who is responsible for 1 pending office action. This represents the entirety of the company's active workload at the USPTO. Practitioners can expect an interaction based on the requirements of WECKER, JENNIFER and the 1 distinct art unit involved. Because there is 1 pending office action for the busiest examiner, the company's strategy is dependent on the individual review of the assigned examiner within the Chemistry & Materials sector. This focus determines the coordination required for the company's current patent filings.
Based on the USPTO statutory response window for each pending office action. 6 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Every pending office action with a known statutory deadline, placed on a days-until-due axis. Dots left of Today are overdue; the further right, the more runway. Cases that share a deadline window stack vertically. 6 of the docket's apps have a known mailing date.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 only | 1 (5%) |
| §101 + other | 5 (24%) |
| §103 only | 5 (24%) |
| §112 only | 2 (10%) |
| Double-patenting + other | 1 (5%) |
| Multi-statute (no §101) | 7 (33%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| GULLEDGE, BRIAN M | 1 | 55.9% | +26.2% |
| MI, QIUWEN | 1 | 68.4% | +50.0% |
| JAFFRI, ZEHRA | 1 | 58.0% | +49.1% |
| TERRELL, EMILY C | 1 | 58.6% | +36.0% |
| MACCAGNO, PIERRE L | 1 | 24.3% | +30.8% |
| KIM, TAEYOON | 1 | 51.4% | +52.2% |
| TATGE, LEXUS MARC | 1 | 25.0% | +100.0% |
| WILSON, MICHAEL C | 1 | 41.5% | +17.8% |
| LEE, TSU-CHANG | 1 | 72.8% | +13.6% |
| WELCH, WILLOW GRACE | 1 | 55.6% | +46.6% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 8 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18450703 | METHOD FOR PREDICTING THE OCCURRENCE OF POSTOPERATIVE ACUTE KIDNEY INJURY AND SYSTEM THEREOF | VAN DUZER, ALEXIS KIM | 29d overdue |
| 18362007 | BALLOON DILATATION CATHETER AND ANGIOPLASTY USING THE SAME | SHAH, NILAY J | 25d overdue |
| 18930574 | HYBRID SHUNT SYSTEM FOR CAROTID ENDARTERECTOMY | JAFFRI, ZEHRA | 19d overdue |
| 18434884 | APPARATUS AND METHOD FOR PREDICTING TENDON RE-RUPTURE BASED ON ARTIFICIAL INTELLIGENCE | WELCH, WILLOW GRACE | 9d |
| 18342930 | LUNG CANCER MODELING USING NORMAL LUNG ORGANOID WITH LUNG CANCER CELLS | CANDELARIA, JULIANA IRENE | 14d |
| 18935122 | COMPOSITION FOR PREVENTING OR TREATING GRAFT-VERSUS-HOST DISEASE COMPRISING TLR5 AGONIST DERIVED FROM FLAGELLIN AS EFFECTIVE COMPONENT | MI, QIUWEN | — |
| 18750890 | DEVICE AND METHOD FOR PREDICTING PATHOLOGIC FRACTURE IN PROXIMAL FEMUR, AND NON-TRANSITORY COMPUTER-READABLE STORAGE MEDIUM STORING PROGRAM FOR PERFORMING THE METHOD | MACCAGNO, PIERRE L | — |
| 18659711 | PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING COLON CANCER INCLUDING EXTRACELLULAR VESICLES LOADED WITH MACC1 INHIBITOR AS ACTIVE INGREDIENT | TATGE, LEXUS MARC | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 8 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18930574 | HYBRID SHUNT SYSTEM FOR CAROTID ENDARTERECTOMY | JAFFRI, ZEHRA | 19d overdue |
| 18434884 | APPARATUS AND METHOD FOR PREDICTING TENDON RE-RUPTURE BASED ON ARTIFICIAL INTELLIGENCE | WELCH, WILLOW GRACE | 9d |
| 19000614 | LIPID NANOPARTICLE COMPOSITION COMPRISING GALLIC ACID DERIVATIVE LIPID AND USE THEREOF | GULLEDGE, BRIAN M | — |
| 18935122 | COMPOSITION FOR PREVENTING OR TREATING GRAFT-VERSUS-HOST DISEASE COMPRISING TLR5 AGONIST DERIVED FROM FLAGELLIN AS EFFECTIVE COMPONENT | MI, QIUWEN | — |
| 18771155 | TUMOR CLASSIFICATION METHOD AND ANALYSIS DEVICE USING MULTI-WAVELENGTH PHOTOACOUSTIC IMAGE AND ULTRASOUND IMAGE | TERRELL, EMILY C | — |
| 18750890 | DEVICE AND METHOD FOR PREDICTING PATHOLOGIC FRACTURE IN PROXIMAL FEMUR, AND NON-TRANSITORY COMPUTER-READABLE STORAGE MEDIUM STORING PROGRAM FOR PERFORMING THE METHOD | MACCAGNO, PIERRE L | — |
| 18737066 | PROTOCOL GENERATING TISSUE SPECIFIC ENDOTHELIAL CELL LINE, NAMED LIOVECS (LUNG TISSUE IPSC ORIGIN VESSEL ORGANOID ENDOTHELIAL CELL) AND BIOVECS (BLOOD VESSEL STEM CELL IPSC ORIGIN VESSEL ORGANOID ENDOTHELIAL CELLS) | KIM, TAEYOON | — |
| 18659711 | PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING COLON CANCER INCLUDING EXTRACELLULAR VESICLES LOADED WITH MACC1 INHIBITOR AS ACTIVE INGREDIENT | TATGE, LEXUS MARC | — |
| Art Unit | Apps |
|---|---|
| 1632 | 2 |
| 1634 | 2 |
| 3771 | 1 |
| 2666 | 1 |
| 3687 | 1 |
| 1631 | 1 |
| 1637 | 1 |
| 1638 | 1 |
| 2128 | 1 |
| 3796 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 19000614 | LIPID NANOPARTICLE COMPOSITION COMPRISING GALLIC ACID DERIVATIVE LIPID AND USE THEREOF | GULLEDGE, BRIAN M | — | §103 | Non-Final OA | — | Pending | Dec 23, 2024 |
| 18935122 | COMPOSITION FOR PREVENTING OR TREATING GRAFT-VERSUS-HOST DISEASE COMPRISING TLR5 AGONIST DERIVED FROM FLAGELLIN AS EFFECTIVE COMPONENT | MI, QIUWEN | — | §101§102 | Non-Final OA | — | Pending | Nov 01, 2024 |
| 18930574 | HYBRID SHUNT SYSTEM FOR CAROTID ENDARTERECTOMY | JAFFRI, ZEHRA | 3771 | §102§103§112 | Final Rejection | 19d overdue | Pending | Oct 29, 2024 |
| 18771155 | TUMOR CLASSIFICATION METHOD AND ANALYSIS DEVICE USING MULTI-WAVELENGTH PHOTOACOUSTIC IMAGE AND ULTRASOUND IMAGE | TERRELL, EMILY C | 2666 | §112 | Final Rejection | — | Pending | Jul 12, 2024 |
| 18750890 | DEVICE AND METHOD FOR PREDICTING PATHOLOGIC FRACTURE IN PROXIMAL FEMUR, AND NON-TRANSITORY COMPUTER-READABLE STORAGE MEDIUM STORING PROGRAM FOR PERFORMING THE METHOD | MACCAGNO, PIERRE L | 3687 | §101§102§103 | Final Rejection | — | Pending | Jun 21, 2024 |
| 18737066 | PROTOCOL GENERATING TISSUE SPECIFIC ENDOTHELIAL CELL LINE, NAMED LIOVECS (LUNG TISSUE IPSC ORIGIN VESSEL ORGANOID ENDOTHELIAL CELL) AND BIOVECS (BLOOD VESSEL STEM CELL IPSC ORIGIN VESSEL ORGANOID ENDOTHELIAL CELLS) | KIM, TAEYOON | 1631 | §103 | Non-Final OA | — | Pending | Jun 07, 2024 |
| 18659711 | PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING COLON CANCER INCLUDING EXTRACELLULAR VESICLES LOADED WITH MACC1 INHIBITOR AS ACTIVE INGREDIENT | TATGE, LEXUS MARC | 1637 | §112 | Non-Final OA | — | Pending | May 09, 2024 |
| 18647191 | METHOD FOR PRODUCING VASCULARIZED RESPIRATORY ORGANOID FUSED WITH BLOOD VESSEL ORGANOID | WILSON, MICHAEL C | 1638 | §103§112 | Non-Final OA | — | Pending | Apr 26, 2024 |
| 18623731 | METHOD FOR GENERATING INFECTIOUS DISEASE PREDICTION KEYWORD THAT CHANGES OVER TIME BASED ON WORD EMBEDDING AND APPARATUS PERFORMING THE SAME | LEE, TSU-CHANG | 2128 | §101 | Non-Final OA | — | Pending | Apr 01, 2024 |
| 18434884 | APPARATUS AND METHOD FOR PREDICTING TENDON RE-RUPTURE BASED ON ARTIFICIAL INTELLIGENCE | WELCH, WILLOW GRACE | 3796 | §101§103§112 | Non-Final OA | 9d | Pending | Feb 07, 2024 |
| 18681231 | METHOD FOR GENERATING OPTIC NERVE PATHWAY USING MRI IMAGE AND OCT IMAGE MATCH | ISLAM, MEHRAZUL NMN | 2662 | §103 | Final Rejection | — | Pending | Feb 05, 2024 |
| 18427981 | ALVEOLAR ORGANOID GENERATION USING ONLY DECM HYDROGELS WITH DROPPING SUSPENSION TECHNOLOGY | JOHNSON, KARA D | 1632 | §102§103 | Final Rejection | — | Pending | Jan 31, 2024 |
| 18559577 | METHOD OF MANUFACTURING ALVEOLAR ORGANOID USING ALVEOLAR CELL-DERIVED INDUCED PLURIPOTENT STEM CELLS | STAVROU, CONSTANTINA E | 1632 | §101§103§112 | Final Rejection | — | Pending | Nov 08, 2023 |
| 18385925 | ELECTRONIC DEVICE FOR AI-BASED RECOMMENDATION OF MELANOMA BIOPSY SITE AND METHOD FOR PERFORMING THE SAME | KUDO, KEN | 2671 | §103 | Non-Final OA | — | Pending | Nov 01, 2023 |
| 18288667 | CANCER-SPECIFIC POLYPEPTIDE AND USE THEREOF | DONOHUE, SEAN R | 1618 | §103§112 | Final Rejection | — | Pending | Oct 27, 2023 |
| 18286677 | PHARMACEUTICAL COMPOSITION COMPRISING NOVEL SD911 COMPOUND AS ACTIVE INGREDIENT FOR PREVENTION OR TREATMENT OF TRANSPLANT REJECTION | KENYON, JOHN S | 1625 | §112DP | Non-Final OA | — | Pending | Oct 12, 2023 |
| 18450703 | METHOD FOR PREDICTING THE OCCURRENCE OF POSTOPERATIVE ACUTE KIDNEY INJURY AND SYSTEM THEREOF | VAN DUZER, ALEXIS KIM | 3682 | §101§103§112 | Non-Final OA | 29d overdue | Pending | Aug 16, 2023 |
| 18362007 | BALLOON DILATATION CATHETER AND ANGIOPLASTY USING THE SAME | SHAH, NILAY J | 3783 | §102§103 | Final Rejection | 25d overdue | Pending | Jul 31, 2023 |
| 18342930 | LUNG CANCER MODELING USING NORMAL LUNG ORGANOID WITH LUNG CANCER CELLS | CANDELARIA, JULIANA IRENE | 1634 | §103§112 | Final Rejection | 14d | Pending | Jun 28, 2023 |
| 18254912 | METHOD FOR FABRICATING MICROROBOT FOR DELIVERY OF CELL THERAPY PRODUCT AND MICROROBOT ACCORDING THERETO | WAX, ROBERT A | 1615 | §103 | Final Rejection | 26d | Pending | May 30, 2023 |
| 17268635 | PHARMACEUTICAL COMPOSITION FOR TREATING CARTILAGE DAMAGE, COMPRISING NASAL SEPTUM CHONDROCYTES | RIGA, MICHAEL ANGELO | 1634 | §103§112 | Final Rejection | — | Pending | Feb 16, 2021 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialThe Catholic University of Korea Industry-Academic Cooperation Foundation has 21 pending office actions as of October 2026, spread across 17 art units and 21 examiners.
Brian M Gulledge has the most, with 1 of The Catholic University of Korea Industry-Academic Cooperation Foundation's pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
